PVPatricia Villar

Patricia Villar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Villar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Laura Gutiérrez

    Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain

    2 shared publications
  • Andrea Acebes-Huerta

    Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain (Villar and Drs Acebes-Huerta and Gutiérrez)

    1 shared publication
  • Andrea Acebes-Huerta

    Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain

    1 shared publication
  • Carmen Rodríguez-Jiménez

    Department of Genetics of Metabolic Diseases, Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz, IdiPAZ, Madrid, Spain (Drs Rodríguez-Jiménez and Rodríguez-Nóvoa)

    1 shared publication
  • Diego Gómez-Coronado

    Servicio de Bioquímica-Investigación, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain

    1 shared publication
  • Gema de la Peña

    Department of Biochemistry-Research, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain (Drs Gómez-Coronado, de la Peña, Martínez-Botas, and Lasunción)

    1 shared publication

Latest Publications

  • Open Access

    A novel ABCA1 variant associated with impaired platelet production contributing to thrombocytopenia in a family with Tangier disease

    by Diego Gómez-Coronado, Carmen Rodríguez-Jiménez, Patricia Villar, María E. Fernández-Suárez, Johannes A. Eble, Gema de la Peña, Javier Martínez-Botas, Andrea Acebes-Huerta, Pedro Prieto-Cazorla, María Villa-Fajardo, et al.


  • Open Access

    Proteomics-wise, how similar are mouse and human platelets?

    by Patricia Martínez-Botía, Patricia Villar, Graciela Carbajo-Argüelles, Zacaria Jaiteh, Andrea Acebes-Huerta, Laura Gutiérrez

    The field of proteomics and its application to platelet biology, is rapidly and promisingly developing. Platelets (and megakaryocytes) are postulated as biosensors of health and disease, and their proteome poses as a tool to identify the specific health-disease hallmarks. Furthermore, the clinical management of certain pathologies where platelets are active players demands the development of alternative treatments, such is the case in patients where the balance thrombosis-bleeding is compromised, and a proteomics approach might aid at the identification of novel targets. Hereby, the mouse and human platelet proteomes and secretomes from public databases are compared, which shows that human and mouse platelets share a highly conserved proteome, considering identified proteins, and most importantly, their relative abundance. These supports, also interspecies wise, the use of the proteomics tool in the field, substantiated by a growing number of clinically relevant studies in humans or preclinical models. While the study of platelets through proteomics seems accessible and direct (i.e. noninvasive blood sampling, enucleated), there are some points of concern regarding the quality control of samples for such proteomics studies. Importantly, the quality of the generated data is improving over the years, which will allow cross-study comparisons. In parallel, the application of proteomics to the megakaryocyte compartment has a promising but long journey ahead. We foresee and encourage the application of platelet proteomics for diagnostic/prognostic purposes even beyond hematopoiesis and transfusion medicine, and as a tool that will procure the improvement of current therapies and the development of alternative treatment options.